Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma

BMC Urology

Volumn 9, Issue 1, 2009, Pages

  Walsh, Naomi ^a   Larkin, Annemarie ^a   Kennedy, Susan ^b   Connolly, Lisa ^a   Ballot, Jo ^b   Ooi, Wei ^b   Gullo, Giuseppe ^b   Crown, John ^a,b   Clynes, Martin ^a   O'Driscoll, Lorraine ^a,c  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; AGED; DRUG EFFECT; GENE EXPRESSION REGULATION; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; TUMOR CELL CULTURE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 68849086857     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-9-6     Document Type: Article

References (35)

1. Cancer statistics, 2007. A Jemal R Siegel E Ward T Murray J Xu MJ Thun, CA Cancer J Clin 2007 57 43 66 10.3322/canjclin.57.1.43 17237035
2. Kidney cancer. NJ Vogelzang WM Stadler, Lancet 1998 352 1691 1696 10.1016/S0140-6736(98)01041-1 9853456
3. Treatment of metastatic renal cell carcinoma. DJ Reeves CY Liu, Cancer Chemother Pharmacol 2009 64 11 25 10.1007/s00280-009-0983-z 19343348
4. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. EE Calle R Kaaks, Nat Rev Cancer 2004 4 579 591 10.1038/nrc1408 15286738
5. Risk factors for renal cell cancer: the multiethnic cohort. VW Setiawan DO Stram AM Nomura LN Kolonel BE Henderson, Am J Epidemiol 2007 166 932 940 10.1093/aje/kwm170 17656615 (Pubitemid 47511687)
6. Obesity, hypertension, and the risk of kidney cancer in men. WH Chow G Gridley JF Fraumeni Jr B Jarvholm, N Engl J Med 2000 343 1305 1311 10.1056/NEJM200011023431804 11058675 (Pubitemid 30808125)
7. Gemcitabine: a phase II study in patients with advanced renal cancer. PH De Mulder L Weissbach G Jakse R Osieka J Blatter, Cancer Chemother Pharmacol 1996 37 491 495 10.1007/s002800050417 8599874 (Pubitemid 26057437)
8. Surgery in advanced and metastatic renal cell carcinoma. DY Chan FF Marshall, Curr Opin Urol 1998 8 369 373 10.1097/00042307-199809000-00002 17039014 (Pubitemid 28479228)
9. The pharmacology of cancer resistance. R O'Connor, Anticancer Res 2007 27 1267 1272 17593618
10. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. L O'Driscoll N Walsh A Larkin J Ballot WS Ooi G Gullo R O'Connor M Clynes J Crown S Kennedy, Anticancer Res 2007 27 2115 2120 17695494
11. MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. S Roy E Kenny S Kennedy A Larkin J Ballot M Perez De Villarreal J Crown L O'Driscoll, Anticancer Res 2007 27 1325 1330 17593626
12. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. A Larkin L O'Driscoll S Kennedy R Purcell E Moran J Crown M Parkinson M Clynes, Int J Cancer 2004 112 286 294 10.1002/ijc.20369 15352042 (Pubitemid 39244369)
13. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. C Calatozzolo M Gelati E Ciusani FL Sciacca B Pollo L Cajola C Marras A Silvani L Vitellaro-Zuccarello D Croci, J Neurooncol 2005 74 113 121 10.1007/s11060-004-6152-7 16193381 (Pubitemid 41478906)
14. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. S Naito N Sakamoto S Kotoh K Goto T Matsumoto J Kumazawa, Eur Urol 1993 24 156 160 8103456
15. Detection of drug resistance and P-glycoprotein in human renal cell carcinomas. M Bak Jr T Efferth G Mickisch J Mattern M Volm, Eur Urol 1990 17 72 75 1969346 (Pubitemid 20058609)
16. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. C Mignogna S Staibano V Altieri G De Rosa G Pannone A Santoro R Zamparese M D'Armiento R Rocchetti E Mezza, BMC Cancer 2006 6 293 17177989 10.1186/1471-2407-6-293 (Pubitemid 46454535)
17. Immunocytochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. S Duensing I Dallmann J Grosse J Buer E Lopez Hanninen M Deckert S Storkel H Kirchner H Poliwoda J Atzpodien, Oncology 1994 51 309 313 10.1159/000227355 7911563
18. Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer? G Hofmockel ID Bassukas A Wittmann J Dammrich, Br J Urol 1997 80 11 17 9240173
19. Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. S Oudard C Levalois JM Andrieu J Bougaran P Validire N Thiounn MF Poupon E Fourme S Chevillard, Anticancer Res 2002 22 121 128 12017273
20. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. H Kanamaru Y Kakehi O Yoshida S Nakanishi I Pastan MM Gottesman, J Natl Cancer Inst 1989 81 844 849 10.1093/jnci/81.11.844 2724349
21. Multiple drug resistance gene expression in human renal cell cancer is associated with the histologic subtype. CF Rochlitz H Lobeck S Peter J Reuter B Mohr E de Kant D Huhn R Herrmann, Cancer 1992 69 2993 2998 10.1002/1097- 0142(19920615)69:12<2993::AID-CNCR2820691222>3.0.CO;2-V 1350506
22. Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. SW Tobe SE Noble-Topham IL Andrulis RW Hartwick KL Skorecki E Warner, Clin Cancer Res 1995 1 1611 1615 9815963
23. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. WJ Kim Y Kakehi H Kinoshita S Arao M Fukumoto O Yoshida, J Urol 1996 156 506 511 10.1016/S0022-5347(01)65915-9 8683726 (Pubitemid 126445369)
24. A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections. E Moran A Larkin G Doherty P Kelehan S Kennedy M Clynes, J Clin Pathol 1997 50 465 471 9378810 10.1136/jcp.50.6.465
25. A new monoclonal antibody, P2A8(6), that specifically recognizes a novel epitope on the multidrug resistance-associated protein 1 (MRP1), but not on MRP2 nor MRP3. L Connolly E Moran A Larkin G Scheffer R Scheper B Sarkadi M Kool M Clynes, Hybrid Hybridomics 2001 20 333 341 10.1089/15368590152740734 11839251
26. P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney. S Ernest E Bello-Reuss, Kidney Int Suppl 1998 65 S11 7 9551426
27. Prognostic variables to predict cancer-related death in incidental renal tumours. K Bensalah AJ Pantuck M Crepel G Verhoest A Mejean A Valeri V Ficarra C Pfister JM Ferriere M Soulie, BJU Int 2008 102 1376 18727618
28. Renal cell carcinoma: molecular and genetic markers as new prognostic and therapeutic tools. A Filosa A Fabiani, Anal Quant Cytol Histol 2008 30 341 343 19160702
29. Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. I Hara H Miyake ME Gleave S Kamidono, Jpn J Cancer Res 2001 92 1220 1224 11714447 (Pubitemid 33133492)
30. Increased expression of lung resistance-related protein in lower grade urothelial carcinoma of the renal pelvis and ureter. CZ Kong Y Zeng XX Wu JQ Li YY Zhu Y Chen, Int J Urol 2004 11 721 727 10.1111/j.1442-2042.2004.00874.x 15379935 (Pubitemid 39387518)
31. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. RE Ferguson SM Jackson AJ Stanley AD Joyce P Harnden EE Morrison PM Patel RM Phillips PJ Selby RE Banks, Int J Cancer 2005 115 155 163 10.1002/ijc.20816 15645438 (Pubitemid 40559682)
32. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. S Pyrhonen E Salminen M Ruutu T Lehtonen M Nurmi T Tammela H Juusela E Rintala P Hietanen PL Kellokumpu-Lehtinen, J Clin Oncol 1999 17 2859 2867 10561363
33. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. JC Yang RM Sherry SM Steinberg SL Topalian DJ Schwartzentruber P Hwu CA Seipp L Rogers-Freezer KE Morton DE White, J Clin Oncol 2003 21 3127 3132 12915604 10.1200/JCO.2003.02.122 (Pubitemid 46606294)
34. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in patients with Metastatic Renal Cell Carcinoma. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski S Oudard S Negrier C Szczylik R Pili GA Bjarnason X Garcia-Del-Muro JA Sosman E Solska G Wilding JA Thompson ST Kim I Chen X Huang RA Figlin, J Clin Oncol 2009 19487381
35. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. LF Kontovinis LK Papazisis PN Touplikioti C Andreadis D Mouratidou AH Kortsari, BMC Cancer 2009 9 82 19284623 10.1186/1471-2407-9-82